Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 80/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

100%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

2Total
P 4 (2)

Trial Status

Not Yet Recruiting1
Terminated1

Clinical Trials (2)

Showing 2 of 2 trials
NCT07365371Phase 4Not Yet Recruiting

A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)

NCT01983579Phase 4TerminatedPrimary

TF (SENSIMED Triggerfish) in Intraocular Anti-VEGF (Vascular Endothelial Growth Factor) Injection

Showing all 2 trials

Research Network

Activity Timeline